| Theme: Translational |
|
|
John Pickup is Professor of Diabetes and Metabolism at King’s College London School of Medicine, Guy’s Hospital, London, UK. He received both his PhD and medical training at the University of Oxford. After a fellowship at the Endocrine Unit, Massachusetts General Hospital, Boston, and an appointment at the Hammersmith Hospital in London he moved to Guy’s Hospital in 1976. He has also been Visiting Professor in the Dept of Physics at the University of Strathclyde, Glasgow since 2005. Professor Pickup has a long-standing interest in the development and clinical application of novel technology for the improved management of diabetes, starting from the development of insulin pump therapy through to in vivo glucose sensors. His current research focuses on insulin pump therapy and continuous glucose monitoring in clinical practice, developing novel fluorescence approaches to glucose sensing, applications of nanomedicine in diabetes, and activation of the innate immune system and inflammation as a cause of type 2 diabetes and its complications. Professor Pickup is the recipient of several research awards, including the R D Lawrence Lectureship of Diabetes UK, the Gotch Prize, the Boehringer Mannheim Fellowship of the Biochemical Society, the BUPA Foundation Research Award and the Diabetes Leadership Award of the Diabetes Technology Society, and book awards from the Charlesworth Foundation, BMA, Royal Society of Medicine and Society of Authors.
|
|
|
Dr Tracey Brown, Chief Scientific Officer and Vice President of Alchemia (Brisbane Australia) has had a career in biomedical research spanning 29 years with experience in the translation of preclinical findings into clinical applications associated with the glycosaminoglycan, hyaluronan (HA). Since completion of her doctorate in carbohydrate biochemistry at the Monash University, Melbourne Australia, Dr Brown has worked in several cancer institutes in both USA and Australia where she gained valuable experience in translational research. In 1999 Dr Brown commenced a research program focused on both the basic and the translational science surrounding the use of HA as a CD44-targeted drug delivery vehicle which actively transports chemotherapeutic drugs to solid tumours; this research culminated in the invention of the HyACT® platform technology. To date Tracey and her team have developed eight anti-cancer agents of which three have entered human clinical trials with the lead drug currently being evaluated in a global pivotal Phase lll. In 2006, the Australian biotechnology company, Alchemia acquired the HyACT® technology and Tracey joined as the VP of Oncology where she is responsible for the non-clinical and clinical development evaluation of lead compounds from both Alchemia’s discovery and HyACT® programs. In addition Tracey holds an adjunct position as an Associate Professor in the Department of Biochemistry and Molecular Biology.
Title of Presentation: Development of Hyaluronan as a CD44-Targeted Drug Delivery Vehicle in the Treatment of Cancer
|
|
|
Dr Jennifer MacDiarmid is joint managing director of EnGeneIC Ltd. EnGeneIC Ltd was founded in 2001 as a privately held Australian bioscience company formed to develop and commercialise novel concepts in the targeted delivery of chemotherapeutics for cancer drugs in-vivo. The company is funded by the Australian government backed venture capital funds, AMWIN and Momentum, private investors and has won support from AusIndustry Commercial Ready Program and the NSW Government. Jennifer has a strong background in R&D innovation with a number of patents and publications. She was formerly a Research Scientist at the CSIRO. Jointly with Dr Himanshu Brahmbhatt, she founded EnGeneIC and co-invented the EDV technology portfolio
Title of Presentation: A novel targeted nanocell for personalised medicine in cancer
|
| NanoMedicine Analytics |
|
|
Professor Justin Gooding graduated with a B.Sc. (Hons) from Melbourne University before spending two years working for ICI Research. He then returned to University obtaining a D.Phil. from the University of Oxford in electrochemistry. A post-doctoral appointment at the Institute of Biotechnology in Cambridge University introduced him to biosensor research. He returned to Australia in 1997 as a Vice-Chancellor’s Post-Doctoral Research Fellow at UNSW before commencing a lectureship at Flinders University in 1998 and then UNSW in 1999. He was one of the recipients of a 1988 RACI Masson Medal, 2004 NSW Young Tall Poppy award, a 2005 Alexander von Humboldt Fellowship, 2007 Erksine Fellow and the 2007 RACI Lloyd Smythe Medal for Analytical Chemistry and the 2009 Eureka Prize for Scientific Research. He is currently and ARC Professorial Fellow in the School of Chemistry at UNSW where he leads a research teams of 20 people.
Title of Presentation: Electrodes that resist protein fouling when used in biological fluids: Applications for biosensing, cell biology and implantable electrodes
|
|
|
Professor Lloyd Hollenberg is the Deputy Director of the Australian Centre of Excellence for Quantum Computation and Communication Technology. He completed his PhD in 1989 at the University of Melbourne in theoretical particle physics and was subsequently awarded a JSPS Fellowship at the KEK accelerator laboratory in Tsukuba, Japan. After his postdoctoral period he returned to the School of Physics where he is now Professor and was awarded an ARC Australian Professorial Fellow (2007-2011). He is an internationally known proponent of quantum technology in the wider context, having also worked on quantum communication systems as a Technical Director of the Quantum Communications Victoria initiative, and recently developing new quantum applications for nanoscale sensing and imaging in the biological realm.
Title of Presentation: Nanodiamonds as fluorescent quantum probes in biology
|
|
|
A/Professor Dusan Losic, completed his PhD at Flinders University in 2003 where he spent several years working as postdoctoral research fellow. From 2007 he received ARC Research Fellowship and worked at Ian Wark Research Institute, University of South Australia, Adelaide. In 2012 he received ARC Future Fellowship and joined the School of Chemical Engineering, the University of Adelaide. He broad research interests across disciplines of chemistry, material science, engineering, biology and medicine are based on fundamental and engineering aspects of synthesis of nanomaterials and their applications.
More specifically, his current research is focused on synthesis of electrochemically self-organized nanoporous and nanotube materials for development new drug delivery systems, optical and electrochemical biosensors and microchip based separations devices.
|
|
|
Matt Trau is currently a Professor of Chemistry at the University of Queensland (UQ) and is also deputy director (nanotechnology) and co-founder of the Australian Institute for Bioengineering and Nanotechnology (AIBN). Matt is internationally recognised for his innovative and cross-disciplinary research at the interface between chemistry, nanotechnology, biology and medicine. He has co-authored more than 100 publications, many of which appear in the highest impact journals in his field, e.g., 2 Nature and 2 Science publications. His major awards and honours include an ARC Federation Fellowship, a Fulbright Research Fellowship to the US, a “Young Tall Poppy" Award for Queensland, a UQ Foundation/Vice Chancellor’s Research Excellence Award, a Paul Harris Fellowship, and a Pink Circle Award for Breast Cancer Research. Among other grants, Matt is currently the lead CI on a 5-year collaborative research grant from the National Breast Cancer Foundation (“Novel Strategies for the Prediction and Control of Advanced Breast Cancer via Nanoscaled Epigenetic Biosensors “).
|
| Macromolecular Design |
|
|
Professor Tanja Weil is Institute Director of the Institute for Organic Chemistry III, Macromolecular Chemistry & Biomaterials, Department of Chemistry, Ulm University in Germany. Professor Weil joined Ulm University in 2010 as Director of the Institute of Organic Chemistry III / Macromolecular Chemistry. She studied chemistry (1993-1998) at the Technical University of Braunschweig in Germany and at the University of Bordeaux I in France. After receiving her Diplom Chemiker degree with Prof. H. Hopf in 1998, she moved to the Max Planck Institute for Polymer Research in Mainz, where she was awarded her PhD working with Prof. K. Müllen. She received the Otto Hahn Medal of the Max Planck Society in 2003. Between 2002 and 2008, she advanced from Section Head of Medicinal Chemistry to Director of Chemical R&D at Merz Pharmaceutics GmbH in Frankfurt, Germany. In 2005, she was also appointed to the Max Planck Institute for Polymer Research as leader of an independent research group leader. From 2008-2010, she moved to the National University of Singapore where she has accepted an Associate Professorship in the Chemistry department. Her major research interests include the synthesis of biopolymers for medicinal applications, protein chemistry as well as protein polymer conjugates.
Title of Presentation: Responsive Protein-Hybrids as Nanocarriers for Targeted Drug Delivery and Bioimaging Applications
|
|
|
David Craik is a Professor at the Institute for Molecular Bioscience, University of Queensland. He obtained his PhD in organic chemistry from La Trobe University in Melbourne, Australia. His contributions to medicinal chemistry and NMR have been recognized by the award of the Adrien Albert medal of the Royal Australian Chemical Institute, the ANZMAG medal of the Australian and New Zealand Society of Magnetic Resonance and the Royal Australian Chemical Institute’s H G Smith Medal and the American Chemical Society’s Ralph F Hirschmann Award in peptide Chemistry. His research interests focus on the application of NMR in drug design, and on toxins, including conotoxins. His group has a particular focus on structural studies of disulfide-rich proteins, and on the discovery and applications of circular proteins and novel protein topologies. He has trained more than 50 PhD students and is the author of >400 scientific publications.
Title of Presentation: Cyclic cystine knot peptides as stabilized frameworks for drug development
|
|
|
Professor Tom Davis is a Director of the Australian Centre for NanoMedicine (ACN) as well as Director of the Centre for Advanced Macromolecular Design (CAMD) at The University of New South Wales. He is a highly regarded polymer chemist with experience from industry and academia. In more recent years Professor Davis’ research has moved towards Polymers for Biotechnology applications with a key interest examining the application of polymer nanotechnologies for drug delivery. Professor Davis is a former ARC Federation Fellow and has published more than 300 refereed papers, eleven book chapters and one co-edited book; “Handbook of Radical Polymerization.” His work has received high levels of interest and influence as measured by citations with a personal ‘h-index’ of 59, a current career citation count of 12000+ and 16 papers cited 100+ times. He has published more than 70 papers in the Journal Macromolecules (designated A* in the recent ERA rankings); this is the highest contribution made to Macromolecules by any Australian researcher. He has made significant contributions to a number of fields including hydrogels and soft contact lenses, pulsed laser polymerisation (determination of rate constants), copolymerisation mechanism, ring-opening polymerisation, catalytic chain transfer, mass spectrometry of polymers, living radical polymerisation, architecture control, glycopolymers, micro-patterned surfaces, nanoparticles, photochromism and most recently bio-hybrid nanostructures. He has trained more than 25 PhD students many of whom are now in senior positions in industry and academia. |
|
|
Professor Sébastien Perrier graduated with his PhD in 2002 from the University of Warwick, England, in polymer chemistry. After one year as a postdoctoral fellow at the University of New South Wales, Australia, he was appointed as lecturer at the University of Leeds, UK, and was promoted to senior lecturer in 2005. In October 2007, he moved to the University of Sydney and was appointed as director of the Key Centre for Polymers & Colloids. Sébastien leads a team working on the design of a wide range of state-of-the-art functional polymeric materials by careful manipulation of their molecular structure. He has published over 100 research papers and book chapters and over 50 conference papers/abstracts. He is a member of the editorial boards of the journals Soft Matter, Macromolecules, European Polymer Journal and Polymer Chemistry, a member of the RACI Polymer Division executive committee (2011 Chair), and was appointed on the Australian Research Council College of Experts in 2011. Awards include the Macro Group UK Young Researcher Award (2006), the Young Tall Poppy Science Award (2009), the Rennie Memorial Medal (2009), and the David Sangster Polymer Science and Technology Award (2009).
Title of Presentation: Engineering Nanostructured Materials for Medical Applications
|
|
|
Greg Qiao is Professor of Macromolecular Chemistry and Engineering and Assistant Dean (Research) Melbourne School of Engineering, The University of Melbourne. Prof Qiao research interests are in the area of synthetic polymer science and engineering. His research applies various polymerisation techniques, including controlled free radical polymerisations, to synthesise novel polymeric architectures, biodegradable and functional polymers. His industrial research is in the synthesis of nanogels for automotive coatings and the novel hydrogels for biological separations. The research in biopolymers is focused on applications in tissue engineering. Greg leads an internationally recognised Polymer Science Group in the Department of Chemical & Biomolecular Engineering at the University of Melbourne and he is currently the president of the Victorian Polymer Group under the Royal Australia Chemical Institute. He is also a project leader of the Cooperative Research Centre for Greenhouse Gas Technologies (CO2CRC) and CRC for Polymers.
|
|
|
Dr Georgina Such completed her PhD (Material Science) in 2006 from the University of New South Wales under the supervision of Adjunct Professor Richard Evans and Professor Tom Davis. Her work focused on combining controlled radical polymerisation and photochromic materials to design new polymer-photochromic conjugates with tunable properties. This work resulted in seven peer-reviewed publications and a number of research awards including the Treleor prize in 2004. Dr Such is currently an Australian Postdoctoral Fellow in the Nanostructured Interfaces and Materials (NIMs) group headed by Professor Frank Caruso. During her time with the NIMS group Dr Such has authored 28 peer-reviewed publications and a number of book chapters, she was also recently awarded one of three L’Oreal Women in Science Fellowships. Her research focuses on the design of multifunctional polymeric delivery systems for drug and gene delivery. Her research interests include design of responsive polymers using controlled radical polymerisation, self-assembly, combining biological and synthetic materials for enhanced properties and materials for efficient therapeutic delivery.
Title of Presentation: Engineering pH Responsive Capsules With Tunable Response To Biological Conditions
|
|
|
Professor Brent S. Sumerlin graduated with a B.S. from North Carolina State University (1998) and obtained a PhD from the University of Southern Mississippi (2003) under the direction of Prof Charles McCormick. After serving as a Visiting Assistant Professor at Carnegie Mellon University under the direction of Prof Krzysztof Matyjaszewski (2003-2005), he joined the Department of Chemistry at Southern Methodist University (Dallas, Texas, USA) as an assistant professor in 2005 and was promoted to associate professor in 2009. Prof Sumerlin has received several awards, including an NSF CAREER Award (2009) and an Alfred P. Sloan Research Fellowship (2010). He is a member of eleven editorial advisory boards, and was recognized as a Kavli Fellow in the summer of 2011. Current research in his group involves the synthesis of functional macromolecules, responsive polymer systems, polymer-protein bioconjugates, and dynamic covalent macromolecular assemblies.
|
|
|
Dr Pall Thordarson (Palli) undertook his BSc (Chemistry) at the University of Iceland before heading to Australia in 1997 to do a PhD in the group of Prof Maxwell Crossley at the University of Sydney. After completing his thesis in 2001 he obtained a Marie Curie Fellowship to work with Prof Roeland Nolte and Prof Alan Rowan at the University of Nijmegen, The Netherlands. Dr Thordarson returned to Australia in 2003 to take up an independent position as a Sesqui Research Fellow with a joint position at the Electron Microscope Unit and the School of Chemistry, University of Sydney. He held an Australian Research Fellowship from the Australian Research Council (ARC) from 2006-2010. Dr Pall Thordarson moved to the School of Chemistry at UNSW to take up a position as a Senior Lecturer in November 2007. Dr Pall Thordarson was awarded the New South Wales Young Tall Poppy Science Award in 2008 and The International Society of Porphyrins and Phthalocaynines (SPP) / Journal of Porphyrins and Phthalocyanines (JPP): SPP/JPP Young Investigator Award for 2010 and the Le Févre Memorial Prize from the Australian Academy of Science for 2012.
The most complex and elegant examples of "nanotechnology" come from Nature.The Thordarson group looks to Nature for inspiration when it comes to solving the problems we are currently dealing with in nanotechnology (eg biosensors or tissue engineering). This is the philosophy of bio-mimetic chemistry, which underpins most of the work in thisgroup. Main research interest are in the broader areas of Nanobiotechnology and Bio-organic chemistry. At the core of nearly all of his work is the art of synthetic organic chemistry, however, techniques from across the whole spectrum of chemistry (physical, inorganic, organic, supramolecular and surface chemistry) as well as biochemistry and biology. Methods (synthesis and/or self-assembly) to direct the assembly of functional molecules are of particular interest to us as are methods to analyse nanostructures, eg by the use of scanning probe microscopy (AFM and STM) and other advanced characterisation tools.
Title of Presentation: A light-driven protein bioconjugate proton pump in a polymersome – what molecular machines can teach us about protein delivery
|
| Medical Imaging |
|
|
Dr Cyrille Boyer received his PhD in polymer chemistry in 2006 from the University of Montpellier II (Ecole National Supèrieure de Chimie de Montpellier) under the supervision of Prof JJ Robin & Prof B Boutevin. His PhD was in collaboration with Solvay-Solexis and devoted to the synthesis of new graft copolymers using grafting “to”. In 2006, he undertook a position with Dupont Performance and Elastomers (Willmington, United States), dealing with the synthesis of original fluorinated elastomers using controlled radical polymerization (eg iodine transfer polymerization). In November 2006, he moved to the Centre for Advanced Macromolecular Design (CAMD), University of New South Wales, as a senior research fellow under the supervision of Prof T P Davis. In 2009, he received an Australian Post-Doctoral Fellowship from the ARC. Since 2010, he has been appointed as a Lecturer in School of Chemical Engineering (UNSW). In 2011 Dr Boyer was appointed a Project Leader in UNSWs Australian Centre for NanoMedicine, in this role he is developing new therapeutic nanoparticles for neuroblastoma cancer, liver fibrosis and prostate cancer. His research interests cover the preparation of well-defined polymers, protein-polymer conjugates and hybrid organic-inorganic nanoparticles using controlled radical polymerization. He has co-authored over 90 reviewed research articles and has filed three international patents and one commercial product. |
|
|
Professor Katharina Gaus is a group leader in the Faculty of Medicine, University of New South Wales. After studying physics and mathematics at the University of Heidelberg, Germany, Prof Gaus received an MPhil (1996) and PhD (1999) from the University of Cambridge, UK while being supported by the German National Scholarship Foundation (Studienstiftung des deutschen Volkes) that supports the top 1% of the German students and the European Trust of the University of Cambridge. After the applied research at Cambridge, she joined the Cell Biology Group led by Prof Roger Dean and Prof Wendy Jessup at the Heart Research Institute in Sydney on a BASF-sponsored fellowship from the German National Scholarship Foundation (1999-2001). In 2001, Prof Gaus spent three months at the University of Urbana-Champagne (USA) on an NHF travel grant working with Prof Enrico Gratton, returing to Australia to take up ARC postdoctoral fellowship linked to a Discovery Grant (2002-2004). In 2005, she established her own research group at the UNSW; having been awarded an NHMRC/NHF co-funded Career Development Award and an ARC Research Fellowship. The focus of the Membrane Cell Biology Group at the Centre for Vascular Research is to understand how lipid domains in the plasma membrane organise and regulate signal transduction processes. Also in 2005, she received the ARC Early Researcher Award, a NSW Young Tall Poppy Award and an Alexander von Humboldt Fellowship, which allowed her to spend six months in the laboratory of Professor Kai Simons at the Max Planck Institute for Cell Biology and Genetics in Germany. Since 2009, Prof Gaus is an NHMRC Senior Research Fellow. In 2010, she received the Young Investigator Award from the Australia and New Zealand Society for Cell and Developmental Biology.
|
|
|
Dr Christoph Hagemeyer obtained a PhD in Biochemistry from the University of Freiburg (Germany) for a thesis on steroid metabolism in the rodent brain. He changed his focus of research from neuroscience to cardiovascular science in 2002 and since then has mainly worked in the field of scFv technology, developing fusion proteins for improved and safer anticoagulation and thrombolysis. He extended his research interests to molecular imaging in 2004 after receiving a Fellowship from the “Centre national de la recherché scientifique” at the University of Bordeaux (France) to undertake studies in magnetic resonance imaging. He moved to Australia in 2005 and is currently a NHMRC Industry Career Development Fellow and Head of the Vascular Biotechnology Laboratory at the Baker IDI Heart and Diabetes Institute in Melbourne. Dr. Hagemeyer has a close collaboration with the ASX-listed biotech company Starpharma, the Industry partner of his current fellowship, investigating proprietary poly-lysine Dendrimers as scFv-targeted agents in molecular imaging. His main research interests are drug delivery, molecular imaging and novel bioconjugation techniques in cardiovascular disease, inflammation and cancer.
|
|
|
Professor Andrew Whittaker is a Group Leader in the Australian Institute for Bioengineering ad Nanotechnology, and the Centre for Advanced Imaging at UQ. He and his group are working to bridge the gap between fundamental physical sciences and applications in the field of new materials for health and technology. His research themes cover three areas involving polymers for electronics, biomaterials and advanced spectroscopy. In the field of polymers for electronics, he and his team collaborate with Intel Corporation, Sematech and IMEC on developing novel polymeric photoresists. He has programs in novel polymeric biomaterials for drug delivery, tissue scaffolds, molecular imaging and recently has received funding to work on spinal cord regeneration. Andrew has strong links with leading international research organizations on three continents, and with small and large electronics and biomedical companies. His group of close to 40 scientists has been supported by government and industry funding of over $18M over the last 10 years.
|
| Smart Surfaces in Regenerative Medicine |
|
|
Professor Alan Trounson is President California Institute for Regenerative Medicine in San Francisco, California. Prior to joining CIRM in 2008, Dr Trounson was Professor of Stem Cell Sciences and Director of the Monash Immunology and Stem Cell Laboratories at Monash University (Australia). Dr Trounson founded the National Biotechnology Centre of Excellence – ‘Australian Stem Cell Centre’. Dr Trounson held various positions at Monash University beginning in 1977 and was appointed Director of the Centre for Early Human Development in 1985. He was awarded a Personal Chair in Obstetrics and Gynaecology/Paediatrics in 1991, and in 2003 was awarded a Personal Chair as Professor of Stem Cell Sciences. He has been a pioneer of human in vitro fertilisation (IVF) and associated reproductive technologies; the diagnosis of inherited genetic disease in pre-implantation embryos; the discovery and production of human embryonic stem cells and of their ability to be directed into neurones, prostate tissue and respiratory tissue. The California Institute for Regenerative Medicine is accelerating the development of new therapies for chronic disease and injury by funding stem cell research programs throughout California.
Title of Presenation: Introduction to embryonic stem cell biology and induced pluripotency. Activities of CIRM
|
|
|
Professor Justin Cooper-White currently holds positions of Associate Dean (Research) of the Faculty of Engineering, Architecture and IT (University of Queensland), Professor within the School of Chemical Engineering (University of Queensland), Group Leader within the Australian Institute for Bioengineering and Nanotechnology (University of Queensland) and Director of the Australian National Fabrication Facility (Queensland Node). Current research interests include the development of novel biomaterials and engineered surfaces for tissue engineered cartilage, cardiac muscle and vascular systems, microbioreactors for stem cell expansion and differentiation, biomicrofluidic devices for fluid property measurement, early disease detection and cell-based diagnostics and the manufacture of microparticle and nanoparticle delivery systems. He has authored or co-authored over 250 research publications and presentations and is often asked to present plenary, keynote and invited lectures at national and international conferences. He is the past President of both The Australasian Society for Biomaterials and Tissue Engineering and The Australian Society of Rheology, a consultant for a number of national and international companies, associate editor of the Korean-Australian Rheology Journal, on the editorial boards of Soft Materials, Rheologica Acta, Scientifica, Current Tissue Engineering and Biomicrofluidics, and a reviewer for major international journals in his fields of expertise. He holds 7 Int. patents in the areas of formulation design for agriproducts, microbioreactors, particle synthesis using microfluidic devices and tissue engineering scaffolds.
Title of Presentation: Lab-on-a-chip for factorial analysis of stem cell responses to microenvironment
|
|
|
Dr Rylie Green received her PhD (Biomedical Engineering) in 2009 from the University of New South Wales under the supervision of Scientia Prof Nigel Lovell and Prof Laura Poole-Warren. Her doctoral research focused on developing bioactive conducting polymers as coatings for neuroprosthetic electrodes. During her postdoctoral studies, Dr Green investigated the in situ polymerization of conducting polymer electrodes directly within the cortical tissue, as a visiting scholar with the Martin Research Group, led by Prof David Martin. Dr Green is currently a research fellow at UNSW and is investigating the application of electrode coating technologies to the developmental bionic eye device as a member of the ARC funded special initiative, Bionic Vision Australia. Additionally, in collaboration with Cochlear Ltd., she is investigating her patented hybrid conducting polymer hydrogel electrode concept, which aims to reduce strain mismatch with neural tissue and improve long-term cell interactions at the neural interface through drug delivery. Her work has resulted in a number of research awards including the Women in Biomedical Engineering award, 2010 from Engineers Australia and a Fresh Science Award, 2010. Dr Green’s research interests encompass conducting polymers, hybrid polymer systems, neural interfaces, neuroprosthetic devices and drug delivery.
Title of Presentation: Conductive polymer hydrogel hybrids as medical electrodes
|
 |
Dietmar Hutmacher is Professor and Chair of Regenerative Medicine at the Institute of Health and Biomedical Innovation of QUT, where he leads the Regenerative Medicine Group, a multidisciplinary team of researchers including engineers, cell biologists, polymer chemists, clinicians, and veterinary surgeons. Professor Hutmacher is a multidisciplinary biomedical engineer, an educator, an inventor, and a creator of new intellectual property opportunities. As a reflection of his pioneering ethos, his recent research efforts have resulted in traditional scientific/academic outputs as well as pivotal commercialisation outcomes. He is one of very few academics in the field of biomaterials/tissue engineering who have taken a research programme from the holistic concept through to clinical application. His team is endeavouring to meet the challenge to provide new bone to replace or restore the function of traumatised bone or bone lost as a consequence of age or disease. Bone tissue engineering concepts developed by his group promise to deliver specifiable replacement tissues and the prospect of efficacious alternative therapies for orthopaedic applications such as non-union fractures, healing of critical-sized segmental defects and regeneration.
Title of Presentation: Translation of novel scaffolds for bone and cartilage engineering into the clinic
|
|
|
Dr Andrew Laslett is a Research Group Leader with CSIRO Materials Science and Engineering, where he leads a human pluripotent stem cell biology research group. He also holds an Adjunct Senior Lecturer position with the Department of Anatomy and Developmental Biology at Monash University and is an Honorary Senior Fellow with the Department of Zoology at Melbourne University. Since 2001, Andrew and his laboratory have focused on elucidating the complex biology of human embryonic stem cells (hESC), examined methods for the differentiation of hESC to renal progenitor cells and more recently begun comparing hESC to reprogrammed human cells termed induced pluripotent stem (iPS) cells. His laboratory is currently focused on exploiting the basic biology of these cell types to create novel cell lines and tools that enhance human pluripotent cell research translation within CSIRO, Australia and internationally. Prior to his current role with CSIRO, Andrew was a Senior Scientist and Group Leader of the Human Embryonic Stem Cell Technology Laboratory at the Australian Stem Cell Centre (ASCC) following Senior Research Fellow appointments in the Laboratory of Embryonic Stem Cell Biology and the Centre for Reproduction and Development, Monash Institute of Medical Research, Monash University. He obtained his BSc (Hons) and PhD (1996) from Monash University prior to undertaking postdoctoral positions in both Hong Kong and Philadelphia, USA.
Title of Presentation: Development of novel reagents for human pluripotent stem cells and reprogramming: Efficiency and safety considerations?
|
|
|
Dr Penny Martens received her PhD in Chemical Engineering from the University of Colorado, USA in 2002. She then moved to the University of New South Wales (UNSW) in 2003, and is currently a Senior Lecturer in the Graduate School of Biomedical Engineering, UNSW. Her area of expertise is in polymer synthesis and characterisation, particularly the rational design of complex biomedical polymer systems. Specifically, she is developing synthetic approaches to modifying biological polymers and their subsequent covalent attachment into base hydrogel systems. These polymer systems have been applied to a variety of biomedical applications (drug release, cartilage tissue engineering, cell encapsulation). Penny is currently serving as Treasurer of the Australasian Society for Biomaterials and Tissue Engineering, and is on the board of Science and Technological Australia. She was also awarded a 2009 NSW Young Tall Poppy Science Award.
Title of Presentation: Encapsulation of pancreatic cells for tissue engineering
|
|
|
Keith McLean has a Ph.D. from the University of Aberdeen, Scotland. Following spells in industry and postdoctoral fellowships in New Zealand and Australia he joined the surface chemistry group at CSIRO Molecular Science in 1996 working on surface modification and characterisation for ophthalmic and other polymeric biomaterials applications. He worked as a member of a team developing an implantable contact lens in the VisionCRC which won the 2004 Royal Societies of Australia Eureka Award for Interdisciplinary Research and the 2009 CSIRO Medal for Research Achievement. Since 2006 he has been the Research Theme Leader for Biomedical Materials and Devices in CSIRO leading an 80 member multidisciplinary team developing biomaterials for tissue engineering, stem cell propagation and implantable devices. His research interests include surface modification and patterning and self-assembling nanomaterials for biomaterials applications. He is Program Leader of the Biomedical Polymers Program in the CRC for Polymers and is the immediate Past President of the Australasian Society for Biomaterials and Tissue Engineering Inc.
Title of Presentation: Biomaterials and surfaces for regenerative medicine
|
|
|
Dr David Nisbet completed his PhD in Materials Engineering at Monash University, Melbourne, Australia in 2009, being awarded the Mollie Holman Medal for best Monash PhD thesis and the Kenneth Hunt Medal for best Engineering PhD thesis. He then received an APD fellowship to work as a Postdoctoral Fellow at Monash University. In 2011 Dr Nisbet moved to the Australian National University, Canberra, Australia to head the Laboratory of Advanced Biomatierals. In 2011 he was awarded the prestigious Fulbright Scholarship and spent 6 months working the University of California Berkeley, as well as the Bethlehem Griffith Research Foundation best young investigator of the year award for medical research. Dr Nisbet’s research deals with the fabrication of synthetic cellular microenvironments that support stem cell survival, adhesion and promote differentiation. Currently he has been investigating the feasibility of using biodegradable electrospun nanofibres and injectable hydrogels (synthetic and natural) for the repair of damaged neural pathways within the brain.
Title of Presentation: Biodegradable electrospun nanofibres and injectible hydrogels for repair of damage neural pathways in the brain
|
|
|
Dr Robert Nordon is a senior lecturer at the Graduate School of Biomedical Engineering, University of New South Wales. His research interests include stem and progenitor cell biology, mathematical modelling of cell fate and bioreactor development for regenerative medicine. He received his PhD and medical training at the University of New South Wales. During his early post-doctoral career he developed a hollow fibre bioreactor for clinical production of stem and progenitor cells. The intellectual property was licensed and commercialised by UNSW leading to the recent launch of the QuantumTM expansion system by Terumo BCT. This closed system is used to expand mesenchymal stem cells under GMP for various therapeutic applications. His current research interest is development of microfluidic platforms for analysis cellular function by live cell imaging, focusing on creating controlled microenvironments for understanding physical and biochemical cues that direct stem and progenitor cell development. He is an associate investigator with the ARC special research initiative into stem cell science (Stem Cells Australia).
Title of Presentation: Chemical and mechanical engineering paradigms for tissue engineering
|
 |
Thomas Schimmel is Professor of Physics and Joint Institute Director, Institute of Applied Physics, Department of Physics, and Head of Department at the Institute of Nanotechnology, Karlsruhe Institute of Technology (KIT), Germany. He is Scientific Director of the Nanoscience Research Network Baden-Wuerttemberg, Germany and Editor-in-Chief of the Beilstein Journal of Nanotechnology.
Title of Presentation: Template-Guided Self-Assembly: Controlling Nanoscale Pattern Formation by Molecular Interaction
|
 |
Kuldip Sidhu, PhD, BSC (Medical) is an associate professor and chair of stem cell biology and is the director of the newly created Stem Cell Laboratory (SCL) at UNSW.
His research focus is on neural stem cells derived from both the embryonic and non-embryonic sources for developing future cell therapies for various neurodegenerative diseases, like Alzheimer’s, Parkinson’s and other neuronal diseases. He has established a state-of-the-art facility to study the cell and developmental biology of stem cells. SCL has expertise to culture, propagate, differentiate, engineer and transplant in animal models the neural stem cells from various sources like human embryonic stem cells, skin-derived neuroprogenitors and human mesenchymal stem cells from bone marrow. In addition, he has expertise in the derivation of new human embryonic stem cell lines including their clonal propagation. SCL also endeavours to develop disease-specific stem cell lines by therapeutic cloning and by induced pluripotent stem (iPS) cell technology for studying the disease processes and in vitro and in drug discovery.
A/Prof Sidhu has produced two books, thirteen book chapters, nine review chapters, two international patents, one proprietary item and 170 original research papers including abstracts in journal of repute and all dealing with mammalian cell and developmental biology including stem cells. He has served on the International Society of Stem Cell Research Sub Committee and the NHMRC Cell Therapy Advisory Committee; he is a member of the editorial board of International Stem Cell Journals, the open stem cell journal and recent patent on regenerative medicine. He was the chair of program committee of the 4th annual meeting of the Australasian society of stem cell research held in Sydney 2011. He has eight national and five international active research collaborations and including three with industry.
He is recognised by many awards eg Medallist for outstanding research from Indian National Science Academy 1981, Best book prize 1996, Medal for best presentation in an international conference on frontiers of reproductive biology 1989, Best invention prize 2007, Finalist of Eureka prize 2009. He has produced 7 PhD, 2 MSC, 4 HONS students and some of them are also recognised with Dean’s list and McConaghy Prize.
|
|
|
Professor Gordon Wallace is an Australian Laureate Fellow and Australian Research Council Federation Fellow. He is currently the Executive Research Director at the ARC Centre of Excellence for Electromaterials Science, and Director of the Intelligent Polymer Research Institute. Professor Wallace’s research interests include organic conductors, nanomaterials and electrochemical probe methods of analysis, and the use of these in the development of Intelligent Polymer Systems. A current focus involves the use of these tools and materials in developing bio-communications from the molecular to skeletal domains in order to improve human performance via medical Bionics. With more than 600 refereed publications, Professor Wallace has attracted more than 14,000 citations and has a h-index of 55. He co-authored a monograph: “Conductive Electroactive Polymers: Intelligent Polymer Systems” with the third edition published in 2008. He has also co-authored a monograph: “Organic Bionics” to be released in April 2012. He has supervised 60 PhD students to completion at the Intelligent Polymer Research Institute.Professor Wallace is an elected Fellow at the Australian Academy of Science, the Australian Academy of Technological Sciences and Engineering, the Institute of Physics (UK) and the Royal Australian Chemical Institute.In addition to being named NSW Scientist of the Year in 2008, Professor Wallace was also appointed to the Korean World Class University System, and received the Royal Australian Chemical Institute HG Smith Prize. In 2004, Professor Wallace received the Royal Australian Chemical Institute Stokes Medal for research in Electrochemistry, after being awarded an ETS Walton Fellowship by Science Foundation Ireland in 2003. The Royal Australian Chemical Institute awarded Professor Wallace the Inaugural Polymer Science and Technology Award in 1992.
Title of presentation: Organic Nanobionics |
| Delivery |
|
|
Professor Maria Kavallaris is a Director of the Australian Centre for NanoMedicine and Head of Tumour Biology and Targeting Program at the Children’s Cancer Institute Australia. She also holds a conjoint academic appointment in the Faculty of Medicine, University of New South Wales. Her research contributions are internationally regarded and include identifying the mechanisms of action and resistance to anticancer drugs that target cell division; discovering new cytoskeleton interactions in cancer; and the development of less toxic cancer therapies using nanotechnology. Her program's research contributions include the identification of novel mechanisms of resistance to anticancer agents that target key proteins involved in cell division in childhood cancer. Professor Kavallaris is an NHMRC Senior Research Fellow and her research contributions have been recognised by international and national awards and prizes including an International Agency for Research on Cancer Fellowship, an American Association for Cancer Research Women in Cancer Research Award, National Health and Medical Research Council (NHMRC) Career Development Award, a Young Tall Poppy Award, and an Australian Museum Eureka Prize. She is regularly invited to speak and chair at international meetings. Professor has authored over 70 publications and her expertise is reflected in invitations to edit a book, contribute book chapters and review articles, including, Nature Reviews Cancer. She has served on numerous committees including the Program Committee for the Annual Meeting of the American Association for Cancer Research and on grant review panels. Professor Kavallaris serves on the Board of the Australian Institute for Policy and Science and has played a major role in advocating for medical research through public outreach and served as President of the Australian Society for Medical Research.
|
|
|
M. Patrick Boisseau is graduate from the Institut National Agronomique and from the Ecole Nationale du Génie Rural, des Eaux et des Forêts. M Boisseau joined the French Atomic Energy Commission (CEA) in 1987 initially as academic research fellow in plant biology, then moving to the Foresight & Strategy Division at the CEA headquarters as an strategic expert in life sciences and environment. From 2001 to 2004, M Boisseau was involved in the design, organisation and funding of the NanoBio innovation Centre in Grenoble. NanoBio brings together engineers, physicists, chemists, biologists and medical doctors to develop new miniaturised tools for biological applications. NanoBio has been established with the University of Grenoble, and fundamental and applied research is undertaken by several institutes and universities in Grenoble in conjunction with industries invovled in the diagnostics and biochips sector. From 2004 to 2008, M Boisseau coordinated the European network of excellence in nanobiotechnology, Nano2Life (www.nano2life.org). M Boisseau is Member of the Executive Board of the European Technology Platforms, and chairman of its working group on nanotechnology based diagnostics and imaging. In 2007, M Boisseau founded the French Technology Platform on Nanomedicine and he is member of its Executive Board. Since 2008, he is in charge of the business development in NanoMedicine at CEA-Leti-MiNaTec, with emphasis on organic nanoparticles for diagnostics and therapy.
Title of Presentations: Lipidots® lipid nanoparticles: tumor-targeting nanocargos for drug and contrast agent delivery and NanoMedicine in Europe |
|
|
Associate Professor Ben J. Boyd is a colloid chemist, gaining his PhD from University of Melbourne, with research interests in colloidal structure in lipid systems and controlling self-assembly to improve drug delivery outcomes. After several years employment in the explosives and pharmaceutical industries, he accepted an academic position at Monash University in 2004. He is currently Group Coordinator for Drug Delivery Sciences at the Monash Institute of Pharmaceutical Sciences at Monash University in Melbourne, Australia. He has published over 70 journal articles, six book chapters, has held three ARC DPs and four Linkage grants as well as NHMRC Project and Development grants, with total research funding exceeding $5M. He is President of the Australian Chapter of the Controlled Release Society, and is a member of the Board of Scientific Advisors of CRS, as well as serving as Secretary of the Colloid Division of the RACI.
Title of Presentation: Translating control of nanostructure in liquid crystalline nanomaterials into smart in vivo drug delivery systems
|
|
|
Dr Cyrille Boyer received his PhD in polymer chemistry in 2006 from the University of Montpellier II (Ecole National Supèrieure de Chimie de Montpellier) under the supervision of Prof JJ Robin & Prof B Boutevin. His PhD was in collaboration with Solvay-Solexis and devoted to the synthesis of new graft copolymers using grafting “to”. In 2006, he undertook a position with Dupont Performance and Elastomers (Willmington, United States), dealing with the synthesis of original fluorinated elastomers using controlled radical polymerization (eg iodine transfer polymerization). In November 2006, he moved to the Centre for Advanced Macromolecular Design (CAMD), University of New South Wales, as a senior research fellow under the supervision of Prof T P Davis. In 2009, he received an Australian Post-Doctoral Fellowship from the ARC. Since 2010, he has been appointed as a Lecturer in School of Chemical Engineering (UNSW). In 2011 Dr Boyer was appointed a Project Leader in UNSWs Australian Centre for NanoMedicine, in this role he is developing new therapeutic nanoparticles for neuroblastoma cancer, liver fibrosis and prostate cancer. His research interests cover the preparation of well-defined polymers, protein-polymer conjugates and hybrid organic-inorganic nanoparticles using controlled radical polymerization. He has co-authored over 90 reviewed research articles and has filed three international patents and one commercial product. |
|
|
Allan Coombes is an Associate Professor at the School of Pharmacy, The University of Queensland. Allan obtained his first degree in Metallurgy and Materials Science from Nottingham University and his PhD in Polymer Physics from Bristol University. Post-doctoral research followed in the area of bioengineering at University College London, bone substitution at the University of Texas in San Antonio, nano and microparticle drug carriers and vaccine formulation at the School of Pharmacy, Nottingham University. A short spell at Quadrant Healthcare working on controlled protein delivery was followed by a research fellowship in tissue engineering at Nottingham University. A/Prof Coombes was appointed Lecturer in Pharmaceutics at Aston University, Birmingham, UK in 1998, Senior lecturer in Pharmaceutics at Sydney University in 2003 and Professor in Pharmaceutics at Kingston University London’s new School of Pharmacy in 2005. In-depth teaching experience in pharmaceutical formulation and physicochemical characterisation is complemented by an extensive publication record in the fields of advanced drug delivery, vaccine formulation, biomaterials and tissue engineering.
Presentation Title: Oral delivery of nanoparticles to the colon for tumour targeting
|
|
|
A/Professor Eva Harth studied chemistry at the University of Bonn and the University of Zurich, Switzerland. In 1994, she joined the group of Prof K. Muellen at the Max-Planck Institute for Polymer Research and obtained her PhD in 1998 for work in the area of fullerene adducts and polymers. A postdoctoral fellowship with CPIMA (NSF-Center for Polymer Interfaces and Macromolecular Assemblies) brought her to the IBM Almaden Research Center, California USA, to work under the direction of Prof Craig J Hawker, focusing on the development of new living free polymerization techniques and approaches to nanoscopic materials. In 2001, she joined XenoPort, Inc. as a Staff Scientist investigating enabling technologies for the increased bioavailability of macromolecular therapeutics. After the extensive industrial experience, she started at Vanderbilt University as Assistant Professor in the Department of Chemistry in 2004 with a secondary appointment in the Department of Pharmacology, Vanderbilt Medical School and was promoted to Associate Professor in 2011. In 2007, she was awarded with the NSF CAREER Award for young faculty and her research advances delivery technologies across challenging biological barriers and towards highly vascular tumors.
|
|
|
A/Professor Jagat Kanwar is the Head of Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research (LIMBR). Dr. He has an international reputation and expertise in investigating fundamental and applied molecular signalling aspects of pathogenesis of cancer, chronic inflammation and neurodegenerative diseases, thereby, leading to the development of treatment strategies from bench to bedside. He has more than 100 publications in high impact factor and peer reviewed international journals, 17 book chapters and 2 edited books. Assoc Prof Kanwar’s research has generated several patents/PCTs with more than five licensed patents for commercialization to BioPharma industry. His group is currently working on drug discovery and nanomedicine for oral and systemic drug delivery of a range of biomacromolecules (proteins/peptides, siRNAs and aptamers) for targeting survivin, HIF-1? and other apoptotic and inflammatory cell signalling molecules in cancer, chronic inflammation and neurodegenerative disorders. For commercially funded grants, his laboratory conducts research in the areas of dairy/plant immunomodulatory bioactives, elderly gut supplements, their role in bone /muscle development and osteoarthritis. He serves as an Editor, Reviewer and Editorial Advisory Board Member of more than 18 international journals and was invited as a speaker in more than 40 conferences and chaired sessions in conferences and scientific meetings on Cancer, Immunology, Vaccines, Microbial infections, Nanotechnology, Nanomedicine and Biotechnology. He has been an active member and delegate in various professional bodies including American Society of Nanomedicine, Australian Nanotechnology network, and a regular grant reviewer for national, international and corporate funding agencies.
Title of Presentation: Survivin and Lactoferrin: From Cancer Nano-Therapy to Corneal Haze/Scarring in Eye
|
|
|
A/Professor Nigel McMillan is with the School of Medical Science at Griffith Univeristy. The laboratory studies RNA interference therapy for cancers and infectious diseases such as Influenza, Respiratory syncytial virus and Hendravirus. We are particularly interested in nanoparticle delivery systems and the interface between RNAi and the immune system. We take a multidisciplinary approach to our research work and we have a diverse set of national and international collaborators in the areas of nanoparticle system development, immunology and cancer biology. |
|
|
Professor Magdalena Plebanski. BScHon (1989, UNAM, Mexico); MBA (Deakin University, 2010, Australia); PhD (1993, Bristol University, UK); Fellow (1993, Oxford University, UK); Senior Fellow (1997, Oxford University, UK); Assoc.Prof. (Victoria University, Australia 1999); Assoc.Prof. Hon (Melbourne University, Australia 2006); Professor (Monash University, Australia 2007). Major awards: Howard Hughes International Scholar (HHMI, USA) 2000-2005. Current from 2003: NHMRC Senior Fellow. Prof. Plebanski’s primary interest is to develop practical and affordable vaccines against complex diseases, specifically malaria and cancer, and to this end she has pioneered the use of synthetic non-inflammatory nanoparticles. Her studies on nanoparticles have also recently opened to door to new nanotechnology applications to prevent allergic airways disease, and potentially asthma (Journal of Immunology, 2012). She has >100 publications (plus abstracts) cited >3200 times, including field changing findings in nanotechnology and vaccines (e.g. Nature Biotechnology 1997 cit=123 and Journal of Immunology 2004 cit=97), and has identified a number of key immune evasion mechanisms that can interfere with vaccine efficacy (>1500 citations e.g. Science 1998, Nature 1999, Nature Medicine 2004, Plos Pathogens 2009). Her 5 families of PCT patents have all successfully progressed to commercialisation nationally and internationally. She pioneered the validation of now widely used techniques for in vitro monitoring of vaccine efficacy such as the ELISPOT, and continues actively setting up and managing human clinical trials of new immuno-modulatory technologies.
|
|
|
|
Professor Martina Stenzel studied chemistry at the University of Bayreuth, Germany, before completing her PhD in 1999 at the Institute of Applied Macromolecular Chemistry, University of Stuttgart, Germany. She then received a DAAD scholarship (German Academic Exchange Service) to work as a postdoctoral Fellow at the UNESCO centre for membrane Science and Technology at the University of New South Wales (UNSW), Sydney Australia. In 2002, she took on a position as a lecturer at the UNSW and worked within the Centre for Advanced Macromolecular Design (CAMD) on complex polymer architectures via RAFT polymerization and honeycomb structured porous films. In 2009 received an ARC Future Fellowship and in 2011 was made Professor. Her research interest is focused on the synthesis of functional polymers with complex architectures such as glycopolymers and other polymers for biomedical applications. She is mainly interested in using core-shell nanoparticles for drug delivery purposes. Martina has published more than 170 papers on macromolecular design and has currently an h-index of 48. Martina is editor of the Australian Journal of Chemistry. She also currently serves and several editorial advisory boards including Macromolecules, Polymers and Progress in Polymer Science, which is the most prestigious journal in polymer science. Martina is currently the honorary general secretary of the Royal Australian Chemical Institute (RACI). She received several awards for her work including the 2011 Australian Academy of Science LeFevre Medal
|
|
|
|
Dr Anita Kamra Verma, Associate Professor, at K.M.College, University of Delhi, has over 22 years of teaching experience and has worked in National Institute of Immunology, New Delhi. She has done her post graduation in 1982 from the University of Delhi,and Ph.D in 1988. She was a Senior Scientist at the School of pharmacy, University of Manchester for two years. She has two Patents on Anti-Cancer Drugs and over 35 publications to her credit. She has been awarded the Charles Darwin Gold medal in 2009. Her research interests include ‘Developing Novel Polymer Therapeutics as Nanomedicines’, making in-vivo models for quantifying nanoparticlulate drug delivery for cancer and Diabetes, developing rationale designs, based on whole body and cellular pharmacokinetics-pharmaco-dynamic profile of drugs.
Title of Presentation: Nanomedicines: Smart Biopolymeric Nano-formulations for Drug Delivery to cancer tissue
|
|
|
Professor Dave Winkler is a Senior Principal Research Scientist and Team Leader with CSIRO Materials Science and Engineering in Melbourne. He is also an Adjunct Professor at Monash University. His team use computational methods to design and model small molecules that modulate biological activity, and to understand the properties of complex materials and nanoparticles. His current research interests: design of cytokine, growth factor, and adhesion molecule mimics to control the growth and fate of stem cells; predicting self-assembly and drug delivery in soft nanoparticles; modelling biological effects of nanoparticles; design of small molecule peptide mimetics; and theoretical modelling of stem cell gene regulation. Dave is Fellow of the Royal Australian Chemical Institute and an associate editor of the journals ChemMedChem and BMC Biophysics.
Title of Presentation: Predicting complex phase behaviour of self-assembling drug delivery nanoparticles
|
| IP Forum |
|
|
| NanoMedicine Trends Internationally |
|
|
M. Patrick Boisseau is graduate from the Institut National Agronomique and from the Ecole Nationale du Génie Rural, des Eaux et des Forêts. M Boisseau joined the French Atomic Energy Commission (CEA) in 1987 initially as academic research fellow in plant biology, then moving to the Foresight & Strategy Division at the CEA headquarters as an strategic expert in life sciences and environment. From 2001 to 2004, M Boisseau was involved in the design, organisation and funding of the NanoBio innovation Centre in Grenoble. NanoBio brings together engineers, physicists, chemists, biologists and medical doctors to develop new miniaturised tools for biological applications. NanoBio has been established with the University of Grenoble, and fundamental and applied research is undertaken by several institutes and universities in Grenoble in conjunction with industries invovled in the diagnostics and biochips sector. From 2004 to 2008, M Boisseau coordinated the European network of excellence in nanobiotechnology, Nano2Life (www.nano2life.org). M Boisseau is Member of the Executive Board of the European Technology Platforms, and chairman of its working group on nanotechnology based diagnostics and imaging. In 2007, M Boisseau founded the French Technology Platform on Nanomedicine and he is member of its Executive Board. Since 2008, he is in charge of the business development in NanoMedicine at CEA-Leti-MiNaTec, with emphasis on organic nanoparticles for diagnostics and therapy.
Title of Presentations: Lipidots® lipid nanoparticles: tumor-targeting nanocargos for drug and contrast agent delivery and NanoMedicine in Europe |
